174 related articles for article (PubMed ID: 18334483)
1. The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis.
Palazuelos J; Davoust N; Julien B; Hatterer E; Aguado T; Mechoulam R; Benito C; Romero J; Silva A; Guzmán M; Nataf S; Galve-Roperh I
J Biol Chem; 2008 May; 283(19):13320-9. PubMed ID: 18334483
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects.
de Lago E; Moreno-Martet M; Cabranes A; Ramos JA; Fernández-Ruiz J
Neuropharmacology; 2012 Jun; 62(7):2299-308. PubMed ID: 22342378
[TBL] [Abstract][Full Text] [Related]
3. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.
Palazuelos J; Aguado T; Pazos MR; Julien B; Carrasco C; Resel E; Sagredo O; Benito C; Romero J; Azcoitia I; Fernández-Ruiz J; Guzmán M; Galve-Roperh I
Brain; 2009 Nov; 132(Pt 11):3152-64. PubMed ID: 19805493
[TBL] [Abstract][Full Text] [Related]
4. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli.
Maresz K; Carrier EJ; Ponomarev ED; Hillard CJ; Dittel BN
J Neurochem; 2005 Oct; 95(2):437-45. PubMed ID: 16086683
[TBL] [Abstract][Full Text] [Related]
5. Antinociceptive effects induced through the stimulation of spinal cannabinoid type 2 receptors in chronically inflamed mice.
Curto-Reyes V; Boto T; Hidalgo A; Menéndez L; Baamonde A
Eur J Pharmacol; 2011 Oct; 668(1-2):184-9. PubMed ID: 21771590
[TBL] [Abstract][Full Text] [Related]
6. Activating cannabinoid receptor 2 alleviates pathogenesis of experimental autoimmune encephalomyelitis via activation of autophagy and inhibiting NLRP3 inflammasome.
Shao BZ; Wei W; Ke P; Xu ZQ; Zhou JX; Liu C
CNS Neurosci Ther; 2014 Dec; 20(12):1021-8. PubMed ID: 25417929
[TBL] [Abstract][Full Text] [Related]
7. Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosis.
Sisay S; Pryce G; Jackson SJ; Tanner C; Ross RA; Michael GJ; Selwood DL; Giovannoni G; Baker D
PLoS One; 2013; 8(10):e76907. PubMed ID: 24130809
[TBL] [Abstract][Full Text] [Related]
8. Ninjurin1 deficiency attenuates susceptibility of experimental autoimmune encephalomyelitis in mice.
Ahn BJ; Le H; Shin MW; Bae SJ; Lee EJ; Wee HJ; Cha JH; Lee HJ; Lee HS; Kim JH; Kim CY; Seo JH; Lo EH; Jeon S; Lee MN; Oh GT; Yin GN; Ryu JK; Suh JK; Kim KW
J Biol Chem; 2014 Feb; 289(6):3328-38. PubMed ID: 24347169
[TBL] [Abstract][Full Text] [Related]
9. Targeting CB(2) receptor as a neuroinflammatory modulator in experimental autoimmune encephalomyelitis.
Lou ZY; Chen C; He Q; Zhao CB; Xiao BG
Mol Immunol; 2011 Dec; 49(3):453-61. PubMed ID: 22024414
[TBL] [Abstract][Full Text] [Related]
10. Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE.
Eltayeb S; Berg AL; Lassmann H; Wallström E; Nilsson M; Olsson T; Ericsson-Dahlstrand A; Sunnemark D
J Neuroinflammation; 2007 May; 4():14. PubMed ID: 17484785
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoid receptor 2 and its agonists mediate hematopoiesis and hematopoietic stem and progenitor cell mobilization.
Jiang S; Alberich-Jorda M; Zagozdzon R; Parmar K; Fu Y; Mauch P; Banu N; Makriyannis A; Tenen DG; Avraham S; Groopman JE; Avraham HK
Blood; 2011 Jan; 117(3):827-38. PubMed ID: 21063029
[TBL] [Abstract][Full Text] [Related]
12. Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.
Gómez-Gálvez Y; Palomo-Garo C; Fernández-Ruiz J; García C
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():200-8. PubMed ID: 25863279
[TBL] [Abstract][Full Text] [Related]
13. TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis.
Takahashi K; Prinz M; Stagi M; Chechneva O; Neumann H
PLoS Med; 2007 Apr; 4(4):e124. PubMed ID: 17425404
[TBL] [Abstract][Full Text] [Related]
14. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset.
Shoemaker JL; Seely KA; Reed RL; Crow JP; Prather PL
J Neurochem; 2007 Apr; 101(1):87-98. PubMed ID: 17241118
[TBL] [Abstract][Full Text] [Related]
15. (-)-β-Caryophyllene, a CB2 Receptor-Selective Phytocannabinoid, Suppresses Motor Paralysis and Neuroinflammation in a Murine Model of Multiple Sclerosis.
Alberti TB; Barbosa WL; Vieira JL; Raposo NR; Dutra RC
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28368293
[TBL] [Abstract][Full Text] [Related]
16. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord.
Yiangou Y; Facer P; Durrenberger P; Chessell IP; Naylor A; Bountra C; Banati RR; Anand P
BMC Neurol; 2006 Mar; 6():12. PubMed ID: 16512913
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Cannabinoid Receptor 2 Deficiency on Neutrophil Recruitment and Inflammation.
Hussain MT; Greaves DR; Iqbal AJ
DNA Cell Biol; 2019 Oct; 38(10):1025-1029. PubMed ID: 31532239
[TBL] [Abstract][Full Text] [Related]
18. Activation of CB2 receptor is required for the therapeutic effect of ABHD6 inhibition in experimental autoimmune encephalomyelitis.
Wen J; Ribeiro R; Tanaka M; Zhang Y
Neuropharmacology; 2015 Dec; 99():196-209. PubMed ID: 26189763
[TBL] [Abstract][Full Text] [Related]
19. Cannabidiol Attenuates Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis Through Induction of Myeloid-Derived Suppressor Cells.
Elliott DM; Singh N; Nagarkatti M; Nagarkatti PS
Front Immunol; 2018; 9():1782. PubMed ID: 30123217
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis.
Benito C; Romero JP; Tolón RM; Clemente D; Docagne F; Hillard CJ; Guaza C; Romero J
J Neurosci; 2007 Feb; 27(9):2396-402. PubMed ID: 17329437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
